CivicPlus Enhances its Emergency and Mass Notification Solution through Partnership with Notification Technology Leader Regroup

CivicPlus, one of the nation’s leaders in integrated technology solutions for local government, has announced that it will be enhancing its CivicReady emergency and mass notification solution through a partnership with Regroup Mass Notification, the award-winning leader in mass notification technology. Read more >>

A NEW HOPE: Gifts of charity bind professor, student

Ben Barnett, right, rode a bike across America in 2016 on a Journey of Hope. Later that year, he spearheaded a 24-hour bike ride to raise funds to replace an eSight reader for professor Joey Arnold, who’d lost his in a devastating house fire. When Barnett’s beloved bike was stolen, Arnold and his family returned the gift, raising funds to purchase a new bike. Today, the pair shares a bond of charity and hope. Read more >>

Regroup Mass Notification and The Lake Forest Group to Present Live Webinar on Campus Security Best Practices

Regroup Mass Notification, the award-winning leader in emergency and day-to-day mass communication technology, today announced that it is joining forces with The Lake Forest Group — a full-service strategic security consulting and a trusted name in both private and public sectors — to present a live webinar on best practices in campus security. Read more >>

Community continues to help attain vision-restoring technology

Williams County and northwest Ohio came together last winter to help legally blind man Ben Murray of Melbern raise funds for a vision-restoring technology called eSight and the community has not stopped giving since.
This year, the area learned of two legally blind young people whose families hoped to purchase the pricey and not-covered eSight as well: Brady Hohl of Wauseon, 9, and Kasandra Romero, 15, of Montpelier. Read more >>

Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the European Commission has granted Orphan Designation in the European Union (“EU”) for the Company’s novel synthetic oral endocannabinoid-mimetic drug, JBT-101 (“Resunab”) for the treatment of systemic sclerosis. Read more >>

Why Corbus Pharmaceuticals Holdings, Inc. Stock Rocketed 412% Upwards in 2016

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) thrilled investors with a 412.1% gain last year, according todata from S&P Global Market Intelligence Opens a New Window. . Positive mid-stage clinical trial results for its lead drug, Resunab, lifted the stock and ignited hope for further expansion in the future. Read more >>